All In Biotech

Drug Trial Radar · NCT03815058

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced Melanoma

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Dec 21, 2018

Primary completion

Jan 21, 2025

Study completion Jan 21, 2025

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Jan 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Conditions

  • Advanced Melanoma

Interventions

  • Autogene cevumeranBiological

    Participants will receive a recommended dose of autogene cevumeran administered by IV infusion at protocol-defined intervals.

  • PembrolizumabDrug

    Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After RandomizationTime frame: From randomization to PD or death (up to approximately 60 months)

Locations

41 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • UCSF Comprehensive Cancer Ctr

    San Francisco, California

  • University of Colorado

    Denver, Colorado

  • Cancer Specialists

    Jacksonville, Florida

  • Moffitt McKinley Outpatient Center

    Tampa, Florida

  • Atlanta Cancer Care

    Alpharetta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Massachusetts General Hospital.

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • Case Western Research University

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Intermountain Surgical Oncology

    Murray, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • St. John of God - Subiaco Hospital

    Subiaco, Western Australia, Australia

  • Antwerp University Hospital

    Edegem, Belgium

  • ZAS Sint Augustinus Wilrijk

    Wilrijk, Belgium

  • Elbe Kliniken Stade-Buxtehude GmbH

    Buxtehude, Germany

  • Universitätsklinikum Koeln

    Cologne, Germany

  • Universitatsklinikum Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Uni Schleswig-Holstein

    Lübeck, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik

    Mainz, Germany

  • Med. Fakultat Mannheim der Universitat Heidelberg

    Mannheim, Germany

  • Fachklinik Hornheide

    Münster, Germany

  • Universitätshautk. Tübingen

    Tübingen, Germany

  • Instituto Oncológico Dr. Rosell

    Barcelona, Spain

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.